Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BONSAI: Cannabidiol for Burnout and Distress in COVID-19 Health Workers
NCT04504877Phase 3Completed
- Sponsor
- Universidade de São Paulo
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cannabidiol in burnout syndrome, psychological distress, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), acute stress disorder (ASD), sponsored by Universidade de São Paulo. Started Jun 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
burnout syndromepsychological distresspost-traumatic stress disorder (PTSD)major depressive disorder (MDD)acute stress disorder (ASD)
Beyond the preview
Go deeper on NCT04504877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504877.